📣 VC round data is live. Check it out!

Syncona Valuation Multiples

Discover Syncona's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like IP Group, NB Private Equity Partners, Kyobo Securities, Hanwha Investment and more.

Syncona Overview

About Syncona

Syncona Ltd is a closed-ended investment company in the United Kingdom. Its investment objective is to achieve superior long-term capital appreciation from its investments. The company invests in life science businesses (including private and quoted companies) and single or multi-asset projects (Life Science Investments).


Founded

2012

HQ

United Kingdom

Employees

37

Financials (FY)

Revenue: $89M
EBITDA: $195M

EV

$827M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Syncona Financials

Syncona reported last fiscal year revenue of $89M and EBITDA of $195M.

In the same fiscal year, Syncona generated $195M in EBITDA and had net loss of ($192M).

Revenue (LTM)


Syncona P&L

In the most recent fiscal year, Syncona reported revenue of $89M and EBITDA of $195M.

Syncona is unprofitable as of last fiscal year, with EBITDA margin of 218% and net margin of (215%).

See analyst estimates for Syncona
Last FY202320242025202620272028
Revenue$89M$56M($48M)($92M)
EBITDA$195M-$195M$195M
EBITDA Margin218%-(410%)(212%)
EBIT Margin218%-(410%)(212%)
Net Profit($192M)($15M)($143M)($193M)
Net Margin(215%)(27%)302%210%

Financial data powered by Morningstar, Inc.

Syncona Stock Performance

Syncona has current market cap of $827M, and enterprise value of $827M.

Market Cap Evolution


Syncona's stock price is $1.36.

Syncona share price increased by 0.2% in the last 30 days, and by 9.9% in the last year.

Syncona has an EPS (earnings per share) of $-0.32.

See more trading valuation data for Syncona
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$827M$827M0.3%0.2%13.2%9.9%$-0.32

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Syncona Valuation Multiples

Syncona trades at 9.3x EV/Revenue multiple, and 4.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Syncona

EV / Revenue (LTM)


Syncona Financial Valuation Multiples

As of June 3, 2026, Syncona has market cap of $827M and EV of $827M.

Syncona has a P/E ratio of (4.3x).

Last FY202320242025202620272028
EV/Revenue9.3x14.7x(17.4x)(9.0x)
EV/EBITDA4.2x-4.2x4.2x
EV/EBIT4.2x-4.2x4.2x
P/E(4.3x)(55.0x)(5.8x)(4.3x)
EV/FCF14.0x40.2x16.1x14.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Syncona Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Syncona Margins & Growth Rates

In the most recent fiscal year, Syncona reported EBITDA margin of 218% and net margin of (215%).

See estimated margins and future growth rates for Syncona

Syncona Margins

Last FY20242025202720282029
EBITDA Margin218%(410%)(212%)
EBIT Margin218%(410%)(212%)
Net Margin(215%)302%210%
FCF Margin66%(108%)(64%)

Syncona Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(184%)94%
EBITDA Growth-0%
EBIT Growth-0%
Net Profit Growth853%35%
FCF Growth149%15%

Data powered by FactSet, Inc. and Morningstar, Inc.

Syncona Operational KPIs

Syncona's revenue per employee in the last FY averaged $2.4M, while opex per employee averaged $2.7M for the same period.

Access forward-looking KPIs for Syncona
Last FY202320242025202620272028
Revenue per Employee$2.4M---
Opex per Employee$2.7M---
G&A Expenses to Revenue5%8%(9%)(5%)
Opex to Revenue113%127%(202%)(110%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
IP Group8.1x9.3x12.0x12.1x
NB Private Equity Partners20.0x---
Kyobo Securities2.7x-3.1x-
Hanwha Investment2.6x---
Treasure ASA----
Eczacıbaşı Yatırım--43.9x-
Abacus Global Management4.9x4.6x8.5x8.0x
Amanat2.5x-5.8x-

This data is available for Pro users. Sign up to see all Syncona competitors and their valuation data.

Start Free Trial

Acquisitions by Syncona

Syncona has acquired 2 companies to date.

Last acquisition by Syncona was on November 22nd 2023. Syncona acquired Freeline for $28M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Syncona

Freeline
AGTC
Description
Freeline is a London-based clinical-stage biotech company developing AAV gene therapies for rare liver disorders like hemophilia B. Its lead candidate, FLT201, entered Phase 1/2 trials in 2022 using a proprietary capsid for high liver tropism and sustained Factor IX expression at 50 percent normal levels. Freeline also advances programs for Fabry disease, with manufacturing in Stevenage, UK, and partnerships with Sarepta Therapeutics. Publicly traded until 2022 acquisition talks.
Applied Genetic Technologies Corporation is a clinical-stage biotechnology firm developing AAV-based gene therapies for retinal and neuromuscular diseases. Headquartered in Alachua, Florida, it advances programs like AGTC-501 for X-linked retinitis pigmentosa and rAAV2tYF-GRK1-RPGR for XLRP, conducting Phase 1/2 trials with FDA orphan drug designations.
HQ CountryUnited KingdomUnited States
HQ City
Stevenage
Alachua, FL
Deal Date22 Nov 202324 Oct 2022
Valuation$28M$24M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Syncona acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Syncona

Syncona has invested in 24 companies to date.

Latest investment by Syncona was on May 17th 2026. Syncona invested in Re-Aim Therapeutics in their $10M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Syncona

Re-Aim Therapeutics
Beacon Therapeutics
Apini Therapeutics
Purespring Therapeutics
Description
Re-Aim Therapeutics is a UK-based biotechnology startup developing functional cures for T cell-mediated autoimmune diseases through selective depletion of pathogenic T-cell subsets. Its lead asset, REA-001, is a monoclonal antibody that targets type-17 T cells to reset immune response and support durable remission.
Beacon Therapeutics is a London-headquartered gene therapy company targeting inherited retinal diseases causing blindness. The firm advances GT005, an AAV-delivered therapy for wet AMD choroidal neovascularization, with Phase 2b trials ongoing in the United States and Europe following seed funding from Oxford Nanopore founders.
Apini Therapeutics is a UK-based biotech developing small-molecule drugs targeting IL-23 and TNF pathways for ulcerative colitis and Crohn's disease. The company's lead candidate, APN-01, advances through Phase II trials for moderate-to-severe IBD patients. Headquartered in Cambridge, Apini collaborates with contract research organizations in Europe.
Purespring Therapeutics is a biotech company developing AAV gene therapies for kidney diseases targeting podocytes. Oxford-based, it pioneers renal gene delivery platforms to treat conditions like focal segmental glomerulosclerosis. Backed by investors, Purespring advances preclinical programs toward clinical trials in collaboration with academic partners.
HQ CountryUnited KingdomUnited KingdomUnited KingdomUnited Kingdom
HQ City
Oxford
London
-
London
Deal Date17 May 20268 Jan 202611 Jun 20259 Oct 2024
RoundSeedSeries CSeedSeries B
Raised$10M$75M$3M$103M
InvestorsOxford Science Enterprises; SynconaAdvent Life Sciences; Forbion Capital Partners; Goldman Sachs Asset Management; Oxford Science Enterprises; Retinal Degeneration Fund; SynconaNorthern Gritstone; SynconaBritish Patient Capital; Forbion Capital Partners; Gilde Healthcare; Sofinnova Partners; Syncona
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Syncona investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Syncona

When was Syncona founded?Syncona was founded in 2012.
Where is Syncona headquartered?Syncona is headquartered in United Kingdom.
How many employees does Syncona have?As of today, Syncona has over 37 employees.
Is Syncona publicly listed?Yes, Syncona is a public company listed on London Stock Exchange.
What is the stock symbol of Syncona?Syncona trades under SYNC ticker.
Who are competitors of Syncona?Syncona main competitors include IP Group, NB Private Equity Partners, Kyobo Securities, Hanwha Investment, Treasure ASA, Eczacıbaşı Yatırım, Abacus Global Management, Amanat, Navigator Global, HMC Capital.
What is the current market cap of Syncona?Syncona's current market cap is $827M.
What is the current revenue of Syncona?Syncona's last fiscal year revenue is $89M.
What is the current EV/Revenue multiple of Syncona?Current revenue multiple of Syncona is 9.3x.
Is Syncona profitable?No, Syncona is not profitable.
How many companies Syncona has acquired to date?As of June 2026, Syncona has acquired 2 companies.
What was the largest acquisition by Syncona?$28M acquisition of Freeline on 22nd November 2023 was the largest M&A Syncona has done to date.
What companies Syncona acquired?Syncona acquired Freeline and AGTC.
In how many companies Syncona has invested to date?As of June 2026, Syncona has invested in 24 companies.
In what companies Syncona invested in?Syncona invested in Beacon Therapeutics, Quell Therapeutics, Gyroscope Therapeutics, Achilles Therapeutics, Anaveon, Freeline, Neogene Therapeutics, Purespring Therapeutics, OMass Therapeutics, Clade Therapeutics, iOnctura, Autolus Therapeutics, SwanBio Therapeutics, Spur Therapeutics, Nightstar Therapeutics, Azeria Therapeutics, Resolution Therapeutics, Blue Earth Diagnostics, Mosaic Therapeutics, Kesmalea Therapeutics, and 4 other companies.

See public comps similar to Syncona

Lists including Syncona

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial